On July 10, BeOne Medicines (06160.HK) rose 3.19% in regular trading, trading at 187.5 HKD/share, with turnover of approximately 3.7 billion HKD. The rally was driven by continued catalysis from Brukinsa clinical data and a strong biotech sector linkage.

On the news front, the company's core product Brukinsa (zanubrutinib) achieved the primary endpoint in the MANGROVE Phase 3 trial evaluating a chemotherapy-free regimen as first-line treatment for mantle cell lymphoma. The combination of Brukinsa plus rituximab reduced disease progression or death risk by 43% versus standard immunochemotherapy (HR=0.57). BeOne Medicines plans to pursue global regulatory submissions in the second half of the year.

Additionally, Huafu Securities recently initiated coverage on BeOne Medicines with a Buy rating and a target price of 297.44 HKD, citing the company's entry into a new era of multi-curve growth, with solid tumor pipeline products advancing into pivotal clinical stages as a second growth driver. Within the Biotechnology sector, peers including Akeso rose 6.29%, Innovent Bio rose 5.21%, and Remegen rose 7.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)